|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Griffin JF, Poruk KE and Wolfgang CL:
Pancreatic cancer surgery: Past, present, and future. Chin J Cancer
Res. 27:332–348. 2015.PubMed/NCBI
|
|
3
|
Dal Molin M, Zhang M, de Wilde RF,
Ottenhof NA, Rezaee N, Wolfgang CL, Blackford A, Vogelstein B,
Kinzler KW, Papadopoulos N, et al: Very long-term survival
following resection for pancreatic cancer is not explained by
commonly mutated genes: Results of whole-exome sequencing analysis.
Clin Cancer Res. 21:1944–1950. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chin V, Nagrial A, Sjoquist K, O'Connor
CA, Chantrill L, Biankin AV, Scholten RJ and Yip D: Chemotherapy
and radiotherapy for advanced pancreatic cancer. Cochrane. Database
Syst Rev. 3:CD0110442018.PubMed/NCBI
|
|
5
|
Grasso C, Jansen G and Giovannetti E: Drug
resistance in pancreatic cancer: Impact of altered energy
metabolism. Crit Rev Oncol Hematol. 114:139–152. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gordon S, Akopyan G, Garban H and Bonavida
B: Transcription factor YY1: Structure, function, and therapeutic
implications in cancer biology. Oncogene. 25:1125–1142. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shi Y, Lee JS and Galvin KM: Everything
you have ever wanted to know about Yin Yang 1. Biochim Biophys
Acta. 1332:F49–F66. 1997.PubMed/NCBI
|
|
8
|
Shi Y, Seto E, Chang LS and Shenk T:
Transcriptional repression by YY1, a human GLI-Kruppel-related
protein, and relief of repression by adenovirus E1A protein. Cell.
67:377–388. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Thomas MJ and Seto E: Unlocking the
mechanisms of transcription factor YY1: Are chromatin modifying
enzymes the key? Gene. 236:197–208. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang JJ, Zhu Y, Xie KL, Peng YP, Tao JQ,
Tang J, Li Z, Xu ZK, Dai CC, Qian ZY, et al: Yin Yang-1 suppresses
invasion and metastasis of pancreatic ductal adenocarcinoma by
downregulating MMP10 in a MUC4/ErbB2/p38/MEF2C-dependent mechanism.
Mol Cancer. 13:1302014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang C, Zhang JJ, Peng YP, Zhu Y, Yin LD,
Wei JS, Gao WT, Jiang KR and Miao Y: A Yin-Yang 1/miR-30a
regulatory circuit modulates autophagy in pancreatic cancer cells.
J Transl Med. 15:2112017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Koelle MR: A new family of G-protein
regulators-the RGS proteins. Curr Opin Cell Biol. 9:143–147. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Siderovski DP, Hessel A, Chung S, Mak TW
and Tyers M: A new family of regulators of G-protein-coupled
receptors? Curr. Biol. 6:211–212. 1996.PubMed/NCBI
|
|
14
|
Watson N, Linder ME, Druey KM, Kehrl JH
and Blumer KJ: RGS family members: GTPase-activating proteins for
heterotrimeric G-protein alpha-subunits. Nature. 383:172–175. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hunt TW, Fields TA, Casey PJ and Peralta
EG: RGS10 is a selective activator of G alpha i GTPase activity.
Nature. 383:175–177. 1996. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hu Y, Xing J, Wang L, Huang M, Guo X, Chen
L, Lin M, Zhou Y, Liu Z, Zhou Z and Sha J: RGS22, a novel
cancer/testis antigen, inhibits epithelial cell invasion and
metastasis. Clin Exp Metastasis. 28:541–549. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hu Y, Xing J, Chen L, Guo X, Du Y, Zhao C,
Zhu Y, Lin M, Zhou Z and Sha J: RGS22, a novel testis-specific
regulator of G-protein signaling involved in human and mouse
spermiogenesis along with GNA12/13 subunits. Biol Reprod.
79:1021–1029. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu Y, Xing J, Chen L, Zheng Y and Zhou Z:
RGS22 inhibits pancreatic adenocarcinoma cell migration through the
G12/13 α subunit/F-actin pathway. Oncol Rep. 34:2507–2514. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kamarajah SK, Burns WR, Frankel TL, Cho CS
and Nathan H: Validation of the American joint commission on cancer
(AJCC) 8th edition staging system for patients with pancreatic
adenocarcinoma: A surveillance, epidemiology and end results (SEER)
analysis. Ann Surg Oncol. 24:2023–2030. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sriram K and Insel PA: G protein-coupled
receptors as targets for approved drugs: How many targets and how
many drugs? Mol Pharmacol. 93:251–258. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang D, Xu Y, Feng L, Yin P, Song SS, Wu
F, Yan P and Liang Z: RGS5 decreases the proliferation of human
ovarian carcinomaderived primary endothelial cells through the
MAPK/ERK signaling pathway in hypoxia. Oncol Rep. 41:165–177.
2019.PubMed/NCBI
|
|
23
|
O'Brien JB, Wilkinson JC and Roman DL:
Regulator of G-protein signaling (RGS) proteins as drug targets:
Progress and future potentials. J Biol Chem. 294:18571–18585. 2019.
View Article : Google Scholar : PubMed/NCBI
|
